Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06486428 · ClinicalTrials.gov registry record
Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies
A clinical trial of Small-cell Lung Cancer, sponsored by Addario Lung Cancer Medical Institute.
- Recruiting
- Registry status
- 30
- Enrollment target
- 20
- Study locations
NCT06486428: Recruiting study of Small-cell Lung Cancer, sponsored by Addario Lung Cancer Medical Institute.
NCT06486428 is a study of Small-cell Lung Cancer that is actively recruiting participants, run by Addario Lung Cancer Medical Institute. The registered enrollment target is 30 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 20 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06486428, a study of Small-cell Lung Cancer, is actively recruiting participants, sponsored by Addario Lung Cancer Medical Institute.
- RECRUITING
- Registry status
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess self-reported preferences and needs of patients with SCLC, regarding choosing and accessing novel therapies in research or standard clinical care settings and supportive gaps in this area, through an initial and 3 month follow up survey.
Primary Outcome
Percentage of overall eligible subjects enrolled. Percentage of primary SCLC eligible subjects enrolled. Percentage of tSCLC eligible subjects enrolled. Percentage of SCLC eligible subjects enrolled compared to percentage of tSCLC eligible subjects enrolled. Percentage of primary SCLC enrolled subjects completed. Percentage of tSCLC enrolled subjects completed. Percentage of SCLC enrolled subjects completed compared to percentage of tSCLC enrolled subjects completed. Overall reasons for early te
Conditions Studied
Study Locations (20)
Alabama
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Alaska
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Arizona
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Arkansas
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
California
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Colorado
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Connecticut
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Delaware
- Https://Alcmi.Org/Clinical-Trials/Current-Studies/Succeed-Study.Html - Multiple Locations
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-23 |
| Est. Completion | 2027-06 |
What NCT06486428 shows while recruiting
NCT06486428 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06486428 names 20 study sites across 20 states, led by Alabama, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT06486428 about?
NCT06486428 is a clinical study titled "Small Cell Lung Cancer Community Engagement to Eliminate Research Discepancies". This study will evaluate if a direct-to-patient, de-centralized, remote approach will improve clinical research outreach and engagement for patients with SCLC, in the context of a bio-specimen collection study. The study will also assess self-reported preferences and needs of patients with SCLC, reg...
What is the current status of trial NCT06486428?
This trial is currently recruiting. The enrollment target is 30 participants. The study started on 2025-05-23. Estimated completion is 2027-06.
What conditions does trial NCT06486428 study?
This clinical trial studies the following conditions: Small-cell Lung Cancer.
Who is sponsoring clinical trial NCT06486428?
This trial is sponsored by Addario Lung Cancer Medical Institute, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06486428 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06486428's enrollment target sits among peer trials
30 66th of 79 higher than 8 of 79 other Small-cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Small-cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
RECRUITING · Phase 3
-
7T Brain MRI Scan for Micro-brain Metastasis (microBM) Detection for Patients With Small-cell Lung Cancer (SCLC), Who Decline Prophylactic Cranial Irradiation (PCI)
RECRUITING
-
A Study of Hospital-at-Home for People Receiving Tarlatamab
RECRUITING · NA
-
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)
RECRUITING · Phase 3
-
Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI